Peter O'Rourke - 15 Mar 2024 Form 4 Insider Report for AXIM BIOTECHNOLOGIES, INC. (AXIM)

Reporting relationship: Director
Issuer ticker: AXIM
Reported as of: 15 Mar 2024
Net transaction value: +$1,225,000,000
SEC form: 4
Accepted by SEC: 19 Mar 2024, 19:24:23 UTC
Prior SEC filing: 23 Sep 2022
Next SEC filing: 30 Jan 2026
Source filing: View source filing
Reporting owner signature: /s/ Peter O'Rourke

Key filing fact

Peter O'Rourke filed Form 4 for AXIM BIOTECHNOLOGIES, INC. (AXIM) on 19 Mar 2024.

Key facts

This page summarizes Peter O'Rourke's Form 4 filing for AXIM BIOTECHNOLOGIES, INC. (AXIM).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 19 Mar 2024, 19:24.

Change

Previous filing in this sequence was filed on 23 Sep 2022.
Current net transaction value: +$1,225,000,000.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

AXIM transaction Derivative

Convertible Note

Award

Transaction value: $1,225,000,000
Shares: +35,000
Change %: +0.78%
Price: $35000.00^*
Shares after: 4,500,000
Date: 15 Mar 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 3,500,000
Exercise price: $0.0100
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Reporting Person acquired a convertible note, face value $35,000. The note is convertible into shares of the Issuer's common stock at a price of $0.01 per share.